Purpose: Initial adaptation period
[1] Orforglipron: A Milestone in Oral GLP-1 RA Development Eli Lilly also presented positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone
Also, hyperglycemia causes increased glucose and sodium reabsorption at the proximal tubule reducing the sodium delivery to the macula densa
Tolerability and Safety Questions Both candidates are likely to be judged partly on gastrointestinal tolerability: nausea, vomiting, diarrhea, constipation, dose escalation, and discontinuation due to adverse events
Many chose to ignore them because the prices were right
doi: 10.2174/187152810793358741